Clinical Research Directory
Browse clinical research sites, groups, and studies.
An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Patients With Myeloid Malignancies
Sponsor: BeOne Medicines
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of BG-75202 (KAT6A/B inhibitor) alone and in combination with other agents in patients with myeloid malignancies.
Official title: A Phase 1a/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BG-75202, Alone and in Combination With Other Agents, in Patients With Myeloid Malignancies
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
118
Start Date
2026-06-23
Completion Date
2028-09-30
Last Updated
2026-06-30
Healthy Volunteers
No
Conditions
Interventions
BG-75202
Administered orally
Hypomethylation Agent (HMA)
Administered Intravenous (IV) or Subcutaneous (SC)
Locations (1)
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciencestuanbo Branch
Tianjin, Tianjin Municipality, China